Primary IOL implantation is successful in children under 2 years of age

Article

The implantation of intraocular lenses (IOL) is a safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

The implantation of intraocular lenses (IOL) is safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

Dr Ramesh Kekunnaya et al., Jasti V Ramanamma Children's Eye Care Center, Hyderabad, India, collected data from 120 eyes of 80 children with congenital/developmental cataract who underwent surgery between January 2006 and December 2007. Of the 120 eyes, 31 were operated on before they were 6 months of age and 89 eyes were operated on after 6 months of age. Rigid polymethylmethacrylate lenses were implanted in 30 eyes and acrylic hydrophobic foldable lenses were implanted in 90 eyes.

Five eyes demonstrated increased anterior chamber inflammation, 8 eyes experienced opacification of the visual axis, 2 eyes had decentration of IOL, 4 eyes experienced pigment dispersion on IOL and posterior synechiae were recorded in 5 eyes.

At the last follow-up there were no cases of glaucoma and no cases of endophthalmitis and retinal detachment. It was concluded that the implantation of IOLs in children below 2 years of age is a viable method for visual performance enhancement.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.